Avis Budget Group, Inc. (CAR)
Legend Biotech: Undervalued Leader In The CAR-T Race
In my opinion, Legend Biotech Corporation is an attractive acquisition target for Johnson & Johnson. Carvykti, which they are jointly developing, is quickly catching up in sales with Darzalex, J&J's blockbuster for the treatment of multiple myeloma. So, sales of Carvykti reached $597 million in Q1, up 61.8% year-on-year, beating my 'best case' scenario by $15 million.
The Big 3: MU, NOW, CAR
Tim Biggam turns to three stocks he believes have overextended moves in recent trading session. To the upside: Micron (MU), which has rallied over 40% in the last month.
Avis Sinks 35%: Short Squeeze Fades as Dilution Risk Takes Center Stage
Shares of Avis Budget Group (NASDAQ:CAR | CAR Price Prediction) are cratering in Thursday trading, with the stock last changing hands near $290 after closing Wednesday at $443.94.
Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet
Cartesian Therapeutics receives a buy rating, driven by a differentiated mRNA CAR-T approach for autoimmune diseases and strong insider/institutional support. RNAC's lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b, surpassing current biologics in durability and efficacy. The ongoing Phase 3 AURORA trial, with FDA SPA agreement and 100 patients, is a pivotal binary catalyst; $126.9M cash runway extends into mid-2027.
Avis's stock has its worst day in 28 years, and what that means for its parabolic rally
Avis Budget's stock chart just sent some bearish signals to suggest a hard landing is in the works.
Avis Climbs 13% as Parabolic Rally Puts an Equity Offering Squarely on the Table
Avis Budget Group (NASDAQ:CAR | CAR Price Prediction) shares are up 13% in early trading Wednesday, continuing a rally that has now become one of the more extraordinary moves in recent market memory.
Avis Budget Group Inc (CAR) Stock Up 17.3% but GF Value Says Overvalued -- GF Score: 70/100
On April 21, 2026, Avis Budget Group Inc (CAR) shares rose 17.3% today, trading at $713.97. This surge comes after a remarkable performance over the past year,
Eli Lilly's Kelonia Therapeutics acquisition seen as strategic bet on next-generation CAR-T: analysts
Eli Lilly and Co (NYSE:LLY)'s acquisition of Kelonia Therapeutics is being seen as a positive step for long-term pipeline building, even as the target's lead assets remain in early clinical development, according to UBS analysts. The $3.25 billion deal, announced on Monday, is among the largest to date in the in vivo CAR-T space.
Avis Brings Back The Short Squeeze — Navitas, Beyond Meat Join In
Meme stock mania is alive and well in April 2026. Avis Budget Group (NASDAQ:CAR) is leading the pack, but several other heavily-shorted stocks are joining in.
Avis Short Squeeze: Why a Stock Offering and Regulatory Scrutiny Could Be Next
The wild trading in Avis Budget Group CAR +7.28% stock continued on Tuesday as shares of the rental-car company gained another 14% and have risen more than six-fold over the past month—and it could result in a regulatory inquiry.
Stock Of The Day: Will The Avis Rally Ever End?
Avis Budget Group, Inc. (NASDAQ:CAR) shares have gained more than 500% in less than a month. They now appear to be in a short-squeeze.
Avis Budget shares touch record high as short squeeze hammers bearish bets
Shares of car rental company Avis Budget hit a record high on Tuesday, having quadrupled so far in April, as analysts pointed to a short squeeze that has dealt steep losses to investors betting against the stock.
